Logo Logo Logo Logo Logo
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Newsletter
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
  • About Us
    • Our Mission
    • About Odylia
    • Our Board
    • Our Team
  • Our Impact
    • reImagine
    • Newsletter
    • Get Involved
    • News
    • Rare Disease Day
  • Research & Services
    • Services Overview
    • Gene Therapy Pipeline
      • RPGRIP1 Gene Therapy
      • USH1C Gene Therapy
    • Brydge Solutions
    • Anc80 Resources
  • Resources
    • The Odylia Library
    • The Odylia Collective
    • Rare Disease Resources
    • Fundraising Resources
    • Webinars and Presentations
  • Donate
Annual Meeting of the American Society of Gene and Cell Therapy Decorative Image

15 May Odylia to attend ASGCT 2018

Posted at 14:27h in Press Releases by Odylia Media

Odylia will be attending the 2018 Annual Meeting of the American Society of Gene and Cell Therapy. We will be meeting with companies and individuals to discuss ways an Odylia partnership can quickly advance therapies for rare disease from the lab to the clinic.

Visit Website

Print page


Latests Posts
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy

    05 May, 2025
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event

    10 April, 2025
  • Joy Cavagnaro

    Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors

    12 March, 2025
Categories
  • Press Releases
  • Uncategorized
Tags
Amgen Prize Board of Directors Concordia Summit February 2025 gene therapy Joy Cavagnaro MIT Solve nephrocystin-1 nephronophthisis NPHP1 NPHP1 Family Foundation Odylia PURA purine-rich element-binding protein alpha purine rich Rare Disease Day Senior-Loken Syndrome SKS Smith Kingsmore Smith Kingsmore Foundation The Odylia Collective
Services
  • Services Overview
  • Brydge Solutions

Visit Odylia's linked in page Visit Odylia's linked in page

Science
  • Research and Development
  • Our Mission
Resources
  • The Odylia Library
  • The Odylia Collective
  • Resources
  • Webinars and Presentations
  • Clinical Trials
Latest News
  • Odylia Therapeutics Announces New Pipeline Project: A Gene Replacement Therapy for NPHP1 Retinal Dystrophy
  • Odylia Therapeutics drives commitment to rare disease drug development through Rare Disease Day event
  • Odylia Therapeutics Welcomes Joy Cavagnaro to Board of Directors
Odylia Therapeutics logo

© 2025 Odylia Therapeutics | Registered 501(c)(3). EIN: 82-2120760 | Site by Hester Designs